

OM336 in Autoimmune Cytopenias

NCT07083960

Status	RECRUITING
Phase	Phase 1
Sponsor	Ouro Medicines
Enrollment	32 participants

Key Eligibility Criteria

Inclusion (4)

- Active autoimmune cytopenia
- Relapsed/refractory after e1 prior treatment
- Body weight e 55 kg
- Willing to comply with and study requirements and procedures

Exclusion (4)

- Previous treatment with a BCMA-targeted therapy
- Clinically significant infection within 3 months of screening
- Major surgery or splenectomy within 3 months of screening or planned during the study
- Pregnant or breastfeeding

Locations (3 total)

The Canberra Hospital, Canberra, Australian Capital Territory, Australia
Liverpool Hospital, Sydney, New South Wales, Australia
Icon Cancer Center South Brisbane, Brisbane, Queensland, Australia